Related Experiment Video
Updated: Sep 2, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.9K
New Developments in Glucagon Treatment for Hypoglycemia.
LesleAnn Hayward Story1, Leah M Wilson2
1Division of Endocrinology, Harold Schnitzer Diabetes Health Center, Oregon Health & Science University, Portland, OR, USA.
Drugs
|August 6, 2022
Summary
New glucagon formulations offer easier administration for severe hypoglycemia treatment in diabetes. These advancements aim to improve patient outcomes, though long-term data and side effects require further study.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Disorders
Background:
- Glucagon is a key hormone for glucose regulation, working alongside insulin.
- Pharmaceutical use of glucagon has been historically limited by its peptide instability.
- Hypoglycemia is a significant complication in managing both type 1 and type 2 diabetes.
Purpose of the Study:
- To review recent advancements in glucagon formulations for diabetes treatment.
- To assess the potential of new glucagon preparations in managing severe and non-severe hypoglycemia.
- To identify challenges and limitations associated with expanded glucagon use.
Main Methods:
- Review of recent developments in glucagon delivery systems.
- Analysis of new intranasal and stable liquid glucagon formulations.
- Evaluation of potential benefits and drawbacks for clinical application.
Main Results:
- Novel intranasal and stable liquid glucagon formulations offer improved ease of use compared to traditional emergency kits.
- These new preparations may simplify the treatment of severe hypoglycemia.
- Liquid formulations show potential for treating non-severe hypoglycemia as well.
Conclusions:
- Recent innovations in glucagon delivery systems promise to enhance hypoglycemia management for diabetic patients.
- Ease of administration and stability are key advantages of new intranasal and liquid formulations.
- Further research on long-term safety, efficacy, and cost-effectiveness is necessary for widespread clinical adoption.
More Related Videos
Related Concept Videos
01:15Hypoglycemia and Glucagon
318
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
318
01:24Glucagon-like Receptor Agonists
400
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
400
01:06Oral Hypoglycemic Agents: Glinides
241
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
241
01:16Hormones Regulating Blood Glucose
3.8K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.8K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
247
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
247
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
277
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
277